34,027 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 34,027 shares of the company’s stock, valued at approximately $1,232,000. Jefferies Financial Group Inc. owned about 0.12% of Eton Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $37,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth about $41,000. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $44,000. Persistent Asset Partners Ltd bought a new stake in Eton Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, State of Wyoming acquired a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $107,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Price Performance

NASDAQ ETON opened at $59.78 on Monday. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $66.37. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The firm has a market capitalization of $1.71 billion, a PE ratio of 157.32 and a beta of 0.86. The company’s 50 day simple moving average is $45.17 and its 200 day simple moving average is $32.02.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The firm had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. As a group, equities research analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on ETON shares. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. B. Riley Financial reissued a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Craig Hallum raised their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Finally, Canaccord Genuity Group increased their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $67.50.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director directly owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Krempa sold 25,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the sale, the insider directly owned 37,025 shares of the company’s stock, valued at $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 125,000 shares of company stock valued at $6,204,250 over the last 90 days. 16.49% of the stock is currently owned by corporate insiders.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.